119 filings
8-K
XFOR
X4 Pharmaceuticals Inc
11 Jun 24
Submission of Matters to a Vote of Security Holders
4:14pm
8-K
XFOR
X4 Pharmaceuticals Inc
22 May 24
Regulation FD Disclosure
8:09am
8-K
XFOR
X4 Pharmaceuticals Inc
9 May 24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
6:58am
8-K
XFOR
X4 Pharmaceuticals Inc
7 May 24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
6:28am
8-K
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Regulation FD Disclosure
8:30am
8-K
s8wxvwnlepvldbw
29 Apr 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDIâ„¢ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
6:30am
8-K
h0h0pue6pur7 lzs2h5x
5 Apr 24
Other Events
4:30pm
8-K
sva8ejxz
1 Apr 24
Regulation FD Disclosure
9:20am
8-K
qx62rj7a
21 Mar 24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
7:43am
8-K
tnuipki0vemy
8 Jan 24
Regulation FD Disclosure
4:08pm
8-K
e5dfayqd cmv
27 Nov 23
Regulation FD Disclosure
5:20pm
8-K
h4v5pi zk
14 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
ryw4m
9 Nov 23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
8:07am
8-K
twerig36qyzyq7qhms
31 Oct 23
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
4:25pm
8-K
qxlsm4l2f bgnc8a
18 Oct 23
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
8:17am
8-K
lchp2
5 Sep 23
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
5:00pm
8-K
wv2zyc fyle
10 Aug 23
Provides Corporate Updates, and Reports Emerging Data from
6:41am
8-K
g19m6
3 Aug 23
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
4:41pm
8-K
vslfh64k
15 Jun 23
Submission of Matters to a Vote of Security Holders
4:38pm
8-K
5n5t8f bfudk2i94p30
1 Jun 23
Regulation FD Disclosure
4:16pm